455 related articles for article (PubMed ID: 35702147)
1. Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants.
Beavis AC; Li Z; Briggs K; Huertas-Díaz MC; Wrobel ER; Najera M; An D; Orr-Burks N; Murray J; Patil P; Huang J; Mousa J; Hao L; Hsiang TY; Gale M; Harvey SB; Tompkins SM; Hogan RJ; Lafontaine ER; Jin H; He B
bioRxiv; 2022 Jun; ():. PubMed ID: 35702147
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T
Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
4. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine.
An D; Li K; Rowe DK; Diaz MCH; Griffin EF; Beavis AC; Johnson SK; Padykula I; Jones CA; Briggs K; Li G; Lin Y; Huang J; Mousa J; Brindley M; Sakamoto K; Meyerholz DK; McCray PB; Tompkins SM; He B
Sci Adv; 2021 Jul; 7(27):. PubMed ID: 34215591
[TBL] [Abstract][Full Text] [Related]
5. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
7. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.
Liu X; Park HS; Matsuoka Y; Santos C; Yang L; Luongo C; Moore IN; Johnson RF; Garza NL; Zhang P; Lusso P; Best SM; Buchholz UJ; Le Nouën C
bioRxiv; 2022 Dec; ():. PubMed ID: 36561185
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
Wang F; Huang B; Deng Y; Zhang S; Liu X; Wang L; Liu Q; Zhao L; Tang L; Wang W; Wang X; Ye F; Hu W; Yang H; Wang S; Ren J; Liu X; Wang C; Guan X; Wang R; Zheng Y; Zhang X; Zheng H; Wu D; An Z; Xu W; Rodewald LE; Gao GF; Yin Z; Tan W
BMC Med; 2023 Jul; 21(1):233. PubMed ID: 37400857
[TBL] [Abstract][Full Text] [Related]
9. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.
Li K; Li Z; Wohlford-Lenane C; Meyerholz DK; Channappanavar R; An D; Perlman S; McCray PB; He B
mBio; 2020 Apr; 11(2):. PubMed ID: 32265331
[TBL] [Abstract][Full Text] [Related]
10. Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters.
Sharma S; Vercruysse T; Sanchez-Felipe L; Kerstens W; Rasulova M; Bervoets L; De Keyzer C; Abdelnabi R; Foo CS; Lemmens V; Van Looveren D; Maes P; Baele G; Weynand B; Lemey P; Neyts J; Thibaut HJ; Dallmeier K
Nat Commun; 2022 Nov; 13(1):6644. PubMed ID: 36333374
[TBL] [Abstract][Full Text] [Related]
11. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
[TBL] [Abstract][Full Text] [Related]
13. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
Corominas J; Garriga C; Prenafeta A; Moros A; Cañete M; Barreiro A; González-González L; Madrenas L; Güell I; Clotet B; Izquierdo-Useros N; Raïch-Regué D; Gallemí M; Blanco J; Pradenas E; Trinité B; Prado JG; Blanch-Lombarte O; Pérez-Caballero R; Plana M; Esteban I; Pastor-Quiñones C; Núñez-Costa X; Taleb RA; McSkimming P; Soriano A; Nava J; Anagua JO; Ramos R; Lluch RM; Comes AC; Romero SO; Gomez XM; Sans-Pola C; Moltó J; Benet S; Bailón L; Arribas JR; Borobia AM; Parada JQ; Navarro-Pérez J; Forner Giner MJ; Lucas RO; Jiménez MDMV; Compán SO; Alvarez-Mon M; Troncoso D; Arana-Arri E; Meijide S; Imaz-Ayo N; García PM; de la Villa Martínez S; Fernández SR; Prat T; Torroella È; Ferrer L
Lancet Reg Health Eur; 2023 May; 28():100613. PubMed ID: 37131861
[TBL] [Abstract][Full Text] [Related]
15. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
16. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
[TBL] [Abstract][Full Text] [Related]
17. Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines.
Ye ZW; Fan Y; Tang K; Ong CP; Luo C; Chung HL; Leong TL; Liang R; Lui WY; Zhou R; Cheng Y; Lu L; Cheung PH; Chan JF; Chen Z; Yuen KY; Yuan S; To KK; Jin DY
Int J Biol Sci; 2022; 18(12):4781-4791. PubMed ID: 35874942
[TBL] [Abstract][Full Text] [Related]
18. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
Boudewijns R; Pérez P; Lázaro-Frías A; Van Looveren D; Vercruysse T; Thibaut HJ; Weynand B; Coelmont L; Neyts J; Astorgano D; Montenegro D; Puentes E; Rodríguez E; Dallmeier K; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():845969. PubMed ID: 35371064
[TBL] [Abstract][Full Text] [Related]
19. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.
Liu X; Park HS; Matsuoka Y; Santos C; Yang L; Luongo C; Moore IN; Johnson RF; Garza NL; Zhang P; Lusso P; Best SM; Buchholz UJ; Le Nouën C
PLoS Pathog; 2023 Jun; 19(6):e1011057. PubMed ID: 37352333
[TBL] [Abstract][Full Text] [Related]
20. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.
Hawman DW; Meade-White K; Clancy C; Archer J; Hinkley T; Leventhal SS; Rao D; Stamper A; Lewis M; Rosenke R; Krieger K; Randall S; Khandhar AP; Hao L; Hsiang TY; Greninger AL; Gale M; Berglund P; Fuller DH; Rosenke K; Feldmann H; Erasmus JH
EBioMedicine; 2022 Sep; 83():104196. PubMed ID: 35932641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
